02235 微泰医疗－Ｂ
按盘价 
6.210 -0.090 (-1.429%) | 日期 | 股东名称 | 披露原因 | 买入／卖出涉及 的股份数目 |
每股平均价 | 持有权益的 股份数目 |
占已发行 股本(%) |
| 08/05/2025 | Shanghai Qichang Investment Consulting Co., Ltd. | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 08/05/2025 | Suzhou Qicheng Investment Management Partnership (Limited Partnership) | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 08/05/2025 | 胡旭波 | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 08/05/2025 | 于佳 | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 08/05/2025 | Suzhou Qiming Ronghe Venture Capital Partnership (Limited Partnership) | 1201(L) | -5,043,252(L) | 11,011,913(L) | 5.29 | |
| 22/04/2025 | LAV Kecheng Hong Kong Limited | 1001(L) | +3,000,000(L) | 3,000,000(L) | 6.87 | |
| 22/04/2025 | LAV Fund VI Opportunities, L.P. | 1001(L) | +3,000,000(L) | 3,000,000(L) | 6.87 | |
| 22/04/2025 | LAV GP VI Opportunities, L.P. | 1001(L) | +3,000,000(L) | 3,000,000(L) | 6.87 | |
| 22/04/2025 | LAV Corporate VI GP Opportunities, Ltd. | 1001(L) | +3,000,000(L) | 3,000,000(L) | 6.87 | |
| 22/04/2025 | Shanghai Liyao Investment Management Co., Ltd (上海礼曜投资管理有限公司) | 1101(L) | 24,776,804(L) | 11.90 | ||
| 22/04/2025 | 陈飞 | 1101(L) | 24,776,804(L) | 11.90 | ||
| 22/04/2025 | 施毅 | 1101(L) | +3,000,000(L) | 20,091,680(L) | 45.98 | |
| 07/03/2025 | OrbiMed Advisors V Limited | 1101(L) | +4,589,900(L) | HKD4.990(L) | 19,651,800(L) | 11.61 |
| 07/03/2025 | OrbiMed Asia GP V, L.P. | 1101(L) | +4,589,900(L) | HKD4.990(L) | 19,651,800(L) | 11.61 |
| 07/03/2025 | OrbiMed Asia Partners V, L.P. | 1101(L) | +4,589,900(L) | HKD4.990(L) | 19,651,800(L) | 11.61 |
| 27/12/2024 | 刘秀 | 1106(L) | 36,000(L) | 0.02 | ||
| 27/12/2024 | 于非 | 1106(L) | 36,000(L) | 0.02 | ||
| 27/12/2024 | 施永辉 | 1106(L) | 626,900(L) | 0.37 | ||
| 14/10/2024 | OrbiMed Advisors V Limited | 1101(L) | +4,500(L) | HKD4.160(L) | 13,541,500(L) | 8.00 |
| 14/10/2024 | OrbiMed Asia Partners V, L.P. | 1101(L) | +4,500(L) | HKD4.160(L) | 13,541,500(L) | 8.00 |
| 14/10/2024 | OrbiMed Asia GP V, L.P. | 1101(L) | +4,500(L) | HKD4.160(L) | 13,541,500(L) | 8.00 |
| 29/07/2024 | OrbiMed Asia Partners V, L.P. | 1001(L) | +12,055,200(L) | HKD3.710(L) | 12,055,200(L) | 7.12 |
| 29/07/2024 | OrbiMed Asia GP V, L.P. | 1001(L) | +12,055,200(L) | HKD3.710(L) | 12,055,200(L) | 7.12 |
| 29/07/2024 | OrbiMed Advisors V Limited | 1001(L) | +12,055,200(L) | HKD3.710(L) | 12,055,200(L) | 7.12 |
| 23/05/2024 | LAV Evergreen (Hong Kong) Co., Limited | 1113(L) | 8,545,840(L) | 8,545,840(L) | 5.05 | |
| 23/05/2024 | Qiming Corporate GP V, Ltd. | 1113(L) | 11,925,181(L) | 7.05 | ||
| 23/05/2024 | 施永辉 | 1711(L) | 590,900(L) | 0.35 | ||
| 23/05/2024 | Lilly Asia Ventures Fund GP, L.P. | 1113(L) | 8,545,840(L) | 8,545,840(L) | 5.05 | |
| 23/05/2024 | QM32 Limited | 1113(L) | 11,925,181(L) | 7.05 | ||
| 23/05/2024 | Lilly Asia Ventures Fund II, L.P. | 1113(L) | 8,545,840(L) | 8,545,840(L) | 5.05 | |
| 23/05/2024 | LAV Corporate GP, Ltd. | 1113(L) | 8,545,840(L) | 8,545,840(L) | 5.05 | |
| 23/05/2024 | 郑攀 | 1711(L) | 41,690,719(L) | 24.63 | ||
| 23/05/2024 | Qiming Venture Partners V, L.P. | 1113(L) | 11,925,181(L) | 7.05 | ||
| 23/05/2024 | Qiming GP V, L.P. | 1113(L) | 11,925,181(L) | 7.05 | ||
| 28/03/2024 | CD Capital GP Ltd | 1001(L) | +3,000,000(L) | 10,026,231(L) | 5.76 | |
| 28/03/2024 | CD Capital Healthcare FUND V, L.P. | 1001(L) | +3,000,000(L) | 10,026,231(L) | 5.76 | |
| 28/03/2024 | CDBI Partners GP, Ltd | 1001(L) | +3,000,000(L) | 10,026,231(L) | 5.76 | |
| 28/03/2024 | CDBI Partners Fund II, L.P. | 1001(L) | +3,000,000(L) | 10,026,231(L) | 5.76 | |
| 28/03/2024 | CDBI Partners Fund I, L.P. | 1001(L) | +3,000,000(L) | 10,026,231(L) | 5.76 | |
| 28/03/2024 | CDBI GP, Ltd | 1001(L) | +3,000,000(L) | 10,026,231(L) | 5.76 | |
| 1 2 | ||||||
| 备注： | (L) - 长仓：包括 (1) 持有股份；(2) 透过持有丶沽出或发行金融合约，有权或有责任购买相关股份。 |
| (S) - 短仓：包括 (1) 借入股份；(2) 透过持有丶沽出或发行金融合约，有权或有责任沽出相关股份。 | |
| (P) - 可供借出的股份 | |
| 即时报价更新时间为 16/05/2025 17:59 | |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |